肿瘤坏死因子受体选择性拮抗剂的研究进展

江海龙; 王宁远; 陆一鸣

doi:10.3969/j.issn.1006-0111.2015.05.003

肿瘤坏死因子受体选择性拮抗剂的研究进展

doi: 10.3969/j.issn.1006-0111.2015.05.003

1.
第二军医大学药学院微生物与生化药学教研室, 上海 200433
2.
第二军医大学药学院微生物与生化药学教研室, 上海 200433;福建中医药大学药学院, 福建福州 350108

基金项目: 国家自然科学基金(30500093);国家科技部"重大新药创制"专项(2009ZX09103-690);上海市科委重点项目(04JC14002);军队"十一五"计划(06Q042);上海市高校优秀青年教师科研专项基金(ejd09011)

Research advance of selective inhibitor of tumornecrosis factor receptor

1.
Department of Microbial and Biochemical Pharmacy, School of Pharmacy, Second Military Medical University, Shanghai 200433, China
2.
Department of Microbial and Biochemical Pharmacy, School of Pharmacy, Second Military Medical University, Shanghai 200433, China;FuJian University of Traditional Chinese Medicine, Fuzhou 350108, China

摘要: 肿瘤坏死因子(TNF)信号通路是很有价值的治疗靶标,抗TNF药物已成功治疗自身免疫和炎症疾病,但传统的抗TNF药物完全封闭TNF信号通路,导致影响自身的免疫调节和监视功能而增加感染、致癌的风险和产生新的自身免疫疾病。选择性抑制sTNF/TNFR1而保留mTNF/TNFR2传导的信号能减少副作用而不降低治疗效果。该文探讨了选择性抑制TNFR1介导的信号通路对治疗TNF相关疾病的意义,分析TNF识别并激活肿瘤坏死因子受体(TNFR)的作用机制,可能会为设计新药提供新的思路。
- 肿瘤坏死因子受体 /
- 选择性拮抗 /
- 药物靶点
Abstract: TNF signaling pathway was a valuable target, and anti-TNF drugs were successfully used to treat autoimmune and inflammatory diseases.But this therapy abrogate some beneficial TNF signaling, leading to increased risk of infection and malignancy, and the onset of new auto-immune diseases. Inhibiting the soluble TNF/TNFR1 axis while saving the beneficial transmembrane TNF/TNFR2 signaling untouched was a new approach.Because it inhibited the pathological effects of TNF and reduced the side effects, and opened the way for the treatment of other diseases in which TNFR2 inhibition was detrimental.The significance of the selective inhibition of TNFR1-mediated signaling pathways for TNF-related diseases was discussed and the mechanism of TNF identification TNFR was clarified, which might provide new ideas for the design of new drugs.
- TNFR /
- selective inhibition /
- drug target

[1]	Apostolaki M, Armaka M, Victoratos P,et al.Cellular mechanisms of TNF function in models of inflammation and autoimmunity[J].Curr Dir Autoimmun, 2010,11(2):1-26.
[2]	Mukai Y,Nakamura T, Yoshikawa M,et al. Solution of the structure of the TNF-TNFR2 complex[J]. Sci Signal,2010,3 (148): 1-10.
[3]	Hehlgans T, Pfeffer K. The intriguing biology of the tumounecrosis factor/tumour necrosis factor receptor superfamily players,rules and the games[J].Immunology,2005,115(1):1-20.
[4]	Mcllwain DR,Lang PA,Maretzky T,et al.IRhom2 regulation of TACE controls TNF-mediated protection against listeria and responses to LPS[J].Science,2012,335(6065):229-232.
[5]	Chen X, Wu X, Zhou Q,et al.TNFR2 is critical for the stabilization of the CD4+Foxp3+ Regulatory T cell phenotype in the inflammatory environmentl[J]. J Immuno,2013, 190(3):1076-1084.
[6]	Faustman D, Davis M. TNF receptor 2 pathway: drug target for autoimmune diseases[J].Nat Rev Drug Discov, 2010, 9(6):482-493.
[7]	Magis C, van der Sloot AM, Serrano L,et al. An improved understanding of TNFL/TNFR interactions using structure-based classi cations[J].Trends Biochem Sci,2012,37(9):353-363.
[8]	Dixon,Hyrich KL, Watson KD,et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)[J]. Ann Rheum Dis,2010,69(3):522-528.
[9]	Takeuchi T, Tatsuki Y, NogamiY,et al. Post marketing surveillance of the safety profile of infliximab in 5 000 Japanese patients with rheumatoid arthritis[J].Ann Rheum Dis,2008, 67(2):189-194.
[10]	Tang W, Lu Y, Tian QY,et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice[J]. Science, 2011, 332(6028): 478-484.
[11]	Deng GM, Zheng LX,Lenardo M,et al. Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain of tumor necrosis factor receptors[J].Nat Med,2005,10(11):1066-1072.
[12]	Hwang JR, Huh JH, Lee Y,et al. Insulin-like growth factor-binding protein-5 (IGFBP-5) inhibits TNF-a-induced NF-κB activity by binding to TNFR1[J]. Biochem Biophys Res Commun, 2011,405(4): 545-551.
[13]	Mukai Y, Shibata H, Nakamura T,et al. Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant[J].J Mol Biol, 2009, 385(4):1221-1229.
[14]	Takasaki W,KajinoY,KajinoK,et al.Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNF-αbinding to its receptor[J]. Nat Biotechnol, 1997, 15:1266-1270.
[15]	Mukaro. Selective activation of tumour necrosis factor receptor-mediated intacellular signalling pathways[D].Adelaide: School of Paediatrics and Reproductive Health,2009.
[16]	Chidnos-Rojas CL,Steward MW,PartidosCD,et al.Apeptidomimetic antagonist of TNF-alpha-mediated cytotoxicity identified from a phage-displayed random peptide library[J]. J Immunol,1998,161(10):5621-5626.
[17]	尹丙姣,黄丽霞,梁慧芳,等.TNFR1封闭肽-hIgGFc融合蛋白和TNFR1封闭肽对TNF-α介导的生物学效应的封闭作用[J].中国免疫学杂志,2008,24(9):776-780.
[18]	Liang H, Yin B, Zhang H,et al. Blockade of tumor necrosis factor (TNF) receptor type1-mediated TNF-α signaling protected wistarrats from diet-Induced obesity and insulin resistance[J]. Endocrinology, 2008, 149(6):2943-2951.
[19]	Roland E,Sabine M,Jens N,et al. A humanized tumor necrosis factor receptor 1 (TNFR1)-specific antagonistic antibody for selective inhibition of tumor necrosis factor (TNF)action[J].J Immunother,2008,31(3):225-234.
[20]	Carter PH, Scherle PA, Muckelbauer JK,et al. Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-a[J]. PNAS, 2001,98(21):11879-11884.
[21]	Murali R, Cheng X, Berezov A,et al. Disabling TNF receptor signaling by induced conformational perturbation of tryptophan-107[J]. PNAS,2005,102(31):10970-10975.

[1]	陈枫, 杨慈荣, 张圳, 陈飞, 刘霞. 基于药物重定位建立以α1酸性糖蛋白为靶点的高通量筛选平台及潜在减肥药物的发现 . 药学实践与服务, 2024, 42(3): 114-120. doi: 10.12206/j.issn.2097-2024.202309057
[2]	张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英. 二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(): 1-6. doi: 10.12206/j.issn.2097-2024.202308062
[3]	史小飞, 陈弋, 向科发, 张慧敏, 高越, 刘霞. 以抗炎为潜在靶点的治疗糖尿病肾病的新药研究进展 . 药学实践与服务, 2023, 41(10): 581-585, 628. doi: 10.12206/j.issn.2097-2024.202109068
[4]	李夏珍, 宋薇薇, 何忠丽. 针灸结合选择性5-羟色胺再摄取抑制剂治疗抑郁症的临床疗效分析 . 药学实践与服务, 2021, 39(4): 366-368. doi: 10.12206/j.issn.1006-0111.202006099
[5]	邓子云, 沈祥国, 徐灿, 田泾. 注射用重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白治疗强直性脊柱炎疑致克罗恩病1例 . 药学实践与服务, 2020, 38(3): 286-288. doi: 10.12206/j.issn.1006-0111.201911045
[6]	张文杰, 孙迪阳, 王培. 炎症小体介导的细胞焦亡在非酒精性脂肪肝病中的作用及机制 . 药学实践与服务, 2020, 38(1): 9-13,41. doi: 10.3969/j.issn.1006-0111.201902051
[7]	李安, 周小青, 孙阔, 杨谨如, 朱勇飞, 陆一鸣. 药物分子与靶蛋白相互作用的研究进展 . 药学实践与服务, 2019, 37(1): 1-4,31. doi: 10.3969/j.issn.1006-0111.2019.01.001
[8]	王洁, 卞莹莹, 张川, 开国银, 陆一鸣. 肿瘤坏死因子及其受体在类风湿性关节炎中的研究进展 . 药学实践与服务, 2017, 35(4): 289-293. doi: 10.3969/j.issn.1006-0111.2017.04.001
[9]	李冉, 张大志. 氮唑类抗真菌药物靶酶CYP51的研究进展 . 药学实践与服务, 2016, 34(2): 106-109. doi: 10.3969/j.issn.1006-0111.2016.02.003
[10]	陶伊琳, 黄幼明, 林惠娥. 选择性二肽基肽酶抑制剂维格列汀与关节痛/骨关节炎发病风险相关性的系统评价 . 药学实践与服务, 2016, 34(6): 540-545. doi: 10.3969/j.issn.1006-0111.2016.06.015
[11]	丁浩, 杨帆, 蔡艺, 柴晓云, 吴秋业. 选择性雌激素受体调节剂研究现状 . 药学实践与服务, 2016, 34(1): 1-4,55. doi: 10.3969/j.issn.1006-0111.2016.01.001
[12]	诸德源, 王一然, 蔡国君, 徐添颖. 烟碱乙酰胆碱受体作为镇痛靶点的研究进展 . 药学实践与服务, 2015, 33(4): 309-312,375. doi: 10.3969/j.issn.1006-0111.2015.04.005
[13]	黄海强, 李慧梁, 汤健, 苏娟, 张卫东. 前列腺癌治疗新靶点——hedgehog通路 . 药学实践与服务, 2008, (4): 249-251.
[14]	丁力, 丁家崇, 郭葆玉. 抗肿瘤药物新靶点半胱天冬酶-10 . 药学实践与服务, 2006, (2): 76-79.
[15]	胡宏岗, 赵庆杰, 张俊, 吴秋业, 刘超美, 徐建明. 抗真菌药物作用靶位的研究进展 . 药学实践与服务, 2005, (2): 65-71.
[16]	田四琦, 刘会臣. 手性药物对映体药效学的立体选择性 . 药学实践与服务, 1999, (6): 346-348.
[17]	张黎, 芮耀诚. 内皮素受体拮抗剂在心血管病临床应用的可能性 . 药学实践与服务, 1997, (6): 340-344.
[18]	杨素兰, 王君松. 转移因子致大疱性表皮松解坏死型药疹死亡一例 . 药学实践与服务, 1995, (1): 48-49.
[19]	. 吡丁醇—支气管扩张药(选择性β₂—肾上腺素受体激动剂) . 药学实践与服务, 1988, (4): 34-34.
[20]	陈光表. 葡萄糖酸钙的高碘酸盐选择性氧化测定 . 药学实践与服务, 1984, (4): 31-34.

点击查看大图

计量

文章访问数: 3240
HTML全文浏览量: 283
PDF下载量: 684
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

肿瘤坏死因子受体选择性拮抗剂的研究进展

doi: 10.3969/j.issn.1006-0111.2015.05.003

Research advance of selective inhibitor of tumornecrosis factor receptor

计量

肿瘤坏死因子受体选择性拮抗剂的研究进展

doi: 10.3969/j.issn.1006-0111.2015.05.003

1. 第二军医大学药学院微生物与生化药学教研室, 上海 200433

2. 第二军医大学药学院微生物与生化药学教研室, 上海 200433;福建中医药大学药学院, 福建福州 350108

English Abstract

Research advance of selective inhibitor of tumornecrosis factor receptor

全文HTML

目录

留言板

肿瘤坏死因子受体选择性拮抗剂的研究进展

doi: 10.3969/j.issn.1006-0111.2015.05.003

Research advance of selective inhibitor of tumornecrosis factor receptor

计量

出版历程

肿瘤坏死因子受体选择性拮抗剂的研究进展

doi: 10.3969/j.issn.1006-0111.2015.05.003

1. 第二军医大学药学院微生物与生化药学教研室, 上海 200433 2. 第二军医大学药学院微生物与生化药学教研室, 上海 200433;福建中医药大学药学院, 福建 福州 350108

English Abstract

Research advance of selective inhibitor of tumornecrosis factor receptor

全文HTML

目录

1. 第二军医大学药学院微生物与生化药学教研室, 上海 200433

2. 第二军医大学药学院微生物与生化药学教研室, 上海 200433;福建中医药大学药学院, 福建福州 350108